PDF (Rus)
Открытый доступ
Только для подписчиков
ПОРАЖЕНИЕ ПОЧЕК ПРИ ПРЕЭКЛАМПСИИ: ВЗГЛЯД НЕФРОЛОГА (ОБЗОР ЛИТЕРАТУРЫ)
Аннотация
Рост интереса нефрологов к проблеме поражения почек при преэклампсии (ПЭ) обусловлен её высокой распространенностью (2–14% от всех беременностей) и непредсказуемым исходом. Патогенез поражения почек при ПЭ мало изучен, однако, установлена роль дисбаланса про- и антиангиогенных факторов – VEGF и sFlt-1 – как одного из важнейших патогенетических механизмов, лежащих в основе развития ПЭ. В статье приводятся современные данные о патогенезе и почечных проявлениях ПЭ на разных сроках её развития в сопоставлении с маркерами плацентарного ангиогенеза. Обсуждается роль дисбаланса системы sFlt-1/VEGF в формировании протеинурии, артериальной гипертензии и ренальной дисфункции при ПЭ, а также «ранней» ПЭ как фактора риска развития хронической болезни почек (ХБП).
Об авторах
Л. И. Меркушева
Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова
Россия
Россия
Меркушева Людмила Игоревна, кандидат медицинских наук, врач-нефролог
117197, Москва, ул. Академика Опарина, д. 4.
Н. Л Козловская
Первый Московский государственный медицинский университет им. И. М. Сеченова
Россия
Россия
Козловская Наталья Львовна - профессор, доктор медицинских наук, кафедра внутренних, профессиональных болезней и пульмонологии медико-профилактического факультета
119991, Москва, ул. Трубецкая, д. 8, стр. 2.
Список литературы
1. James PR, Nelson-Piercy C. Management of hypertension before, during and after pregnancy. Heart 2004; 90: 1499–1504. doi.org/10.1136/hrt.2004.035444
2. Noris M, Perico N, Remuzzi G. Mechanisms of disease: pre-eclampsia. Nature Clin Pract Nephrol 2005; 1(2): 98–114. doi.org/10.1038/ncpneph0035
3. Нertig A, Watnick S, Strevens H. et al. How should women with pre-eclampsia be followed up? New insights from mechanistic studies. Nature Clin Pract Nephrol 2008; 4 (9): 503—509. doi.org/10.1038/ncpneph0880
4. Levine RJ, Maynard SE, Quan C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683. doi.org/10.1056/NEJMoa031884
5. Maynard SE, Min JY, Lim KH et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelian dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658. doi.org/10.1172/JCI17189
6. Karumanchi SA, Maynard SE, Stillman IE et al. Preeclampsia: a renal perspective. Kidney Intern 2005; 67: 2101–2113. doi.org/10.1111/j.1523-1755.2005.00316.x
7. Phyllis A. Preeclampsia: a «nephrocentric» view. Adv Chronic Kidney Rev 2013; 20(3):280–286 doi.org/10.1053/j.ackd.2013.01.013
8. Тареева ИЕ. Нефрология: Руководство для врачей. Медицина, М., 2000; 464–473 [Tareeva I.E. Rukovodstvo dlya vrachej. Medicina, M., 2000; 464–473]
9. Fisher KA, Ahuja S, Luger AM et al. Nephrotic proteinuria with preeclampsia. Am J Obstet Gynecol 1977; 129: 643–646. doi.org/10.1016/0002-9378(77)90646-9
10. Cohen AW, Burton NG. Nephrotic syndrome due to preeclamptic nephropathy in hydatidiform mole and coexistent fetus. Obstet Gynaecol 1979; 53: 130–134
11. Козловская НЛ, Меркушева ЛИ, Кирсанова ТВ и др. Влияние дисбаланса плацентарных факторов ангиогенеза на клинические проявления «ранней» и «своевременной» преэклампсии. Нефрология и диализ 2013; 15(3): 206–215 [Kozlovskaya NL, Merkusheva LI, Kirsanova TV i dr. Vliyanie disbalansa platsentarnykh faktorov angiogeneza na klinicheskie proyavleniya «rannej» i «svoevremennoj» preehklampsii. Nephrology and Dialysis 2013; 15(3):206–215]
12. Козловская НЛ, Меркушева ЛИ, Кирсанова ТВ и др. Дисбаланс плацентарных факторов ангиогенеза и клинические особенности «ранней» и «своевременной» преэклампсии. Взгляд нефролога. Архив акушерства и гинекологии им. В.Ф.Снегирева 2014; 1:13–21 [Kozlovskaya NL, Merkusheva LI, Kirsanova TV i dr. Disbalans platsentarnykh faktorov angiogeneza i klinicheskie osobennosti «rannej» i «svoevremennoj» preehklampsii. Vzglyad nefrologa. V.F.Snegirev Archives of Obstetrics and Gynecology 2014; 1:13–21]
13. Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980; 18: 152–161. doi.org/10.1038/ki.1980.124
14. Moran P, Baylis PH, Lindheimer MD. Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 2003;14: 648–652. doi.org/10.1097/01.ASN.0000051724.66235.E0
15. National Kidney Foundation. Kidney Disease Outcome Quality Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49 (2): 1–180. DOI: 10.1053/j. ajkd.2006.12.005
16. Smith МС, Moran Р, Ward MK, Davison JM. Assessment of glomerular filtration rate during pregnancy using the MDRD formula. BJOG: An International Journal of Obstetrics & Gynaecology 2008; 115(1): 109–112. doi.org/10.1111/j.1471-0528.2007.01529.x
17. Schaffer N, Dill L, Cadden J. Uric acid clearance in normal pregnancy and preeclampsia. J Clin Invest 1943; 22:201–206. doi.org/10.1172/JCI101383
18. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007;18:2281–2284. doi.org/10.1681/ASN.2007020255
19. Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestation and molecular mechanisms. Nephron Clin Pract 2007;106:72–81. doi.org/10.1159/000101801
20. Strevens H, Wide-Swensson D, Hansen A еt al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. Br J Obst Gynecol 2003;110: 831–836. doi.org/10.1111/j.1471-0528-.2003.02162.x
21. Gaber LW, Spargo BH: Pregnancy-induced nephropathy: The significance of focal segmental glomerulosclerosis. Am J Kidney Dis 1987; 9: 317–323. doi.org/10.1016/S0272-6386-(87)80129-4
22. Heaton JM, Turner DR. Persistent renal damage following pre-eclampsia: A renal biopsy study of 13 patients. J Pathol1985; 147: 121–126. doi.org/10.1002/path.1711470207
23. Saritas T, Moeller MJ. Pre-eclamsia, podocyturia and the role of parietal epithelial cells. J Nat Rev Nephrol 2014;10:615– 616.doi:10.1038/nrneph.2014.163
24. Simon M, Grone H-J, Johren O et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 37:24–250. doi.org/10.1152/ajprenal.1995.268.2.F240
25. Nakagawa T, Lan HY, Zhu HJ et al. Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells. Am J Physiol Renal Physiol 2004; 287(4): 658–664. doi.org/10.1152/ajprenal.00040.2004
26. Kearney JB, Kappas NC, Ellerstrom C et al. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 2004; 103(12): 4527 – 4535. doi.org/10.1182/blood-2003-07-2315
27. Li B, Ogasawara AK, Yang R et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002;39(6):1095–1100. doi.org/10.1161/01.HYP.0000018588.56950.7A
28. Suga S, Kim Y, Joly A et al. Vascular endothelial grown factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney International 2001;60: 1297–1308. doi.org/10.1046/j.1523-1755.2001.00935.x
29. Eremina V, Jefferson A, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129–1139. doi.org/10.1056/NEJMoa0707330
30. Bollee, G, Patey N, Cazajous G et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2008; 24: 682–685. doi.org/10.1093/ndt/gfn657 31.
31. Ballermann BJ. Glomerular endothelial cell differentiation. Kidney Int 2005; 67:1668–1671. doi.org/10.1111/j.1523-1755-.2005.00260.x
32. Muller-Deile J, Schiffer M. Renal involvement in preeclampsia: similarities to VEGF ablation therapy. J of Pregnancy 2011; 2011: 6 pages. Article ID 176973. doi.org/10.1155/2011/176973
33. Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in Perinatology 2009;33(3):130–137. doi. org/10.1053/j.semperi.2009.02.010
34. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–434. doi. org/10.1056/NEJMoa021491
35. Robinson E, Matulonis U, Ivy P et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial grown factor receptor inhibitor. Clinical Journal of the American Society of Nephrology 2010; 5(3): 477–483. doi. org/10.2215/CJN.08111109
36. Patel TV, Morgan GA, Demetri GD et al. A preeclampsialike syndrome characterized by reversible hypertension and proteinuria indused by the multitargeted kinase inhibitors sunitinib and soferenib. Journal of the National Cancer Institute 2008;100 (4):282–284. doi.org/10.1093/jnci/djm311
37. Yang R, Ogasawara AK, Zioncheck TF et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002;39(3):815–820. doi.org/10.1161/hy0302.105398
38. Okuda Y, Tsurumaru K, Suzuki S et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sciences 1998; 63(6):477–484.doi.org/10.1016/S0024-3205(98)00296-3
39. Зозуля ОВ, Рогов ВА, Пятакова НВ, Тареева ИЕ. Оксид азота: роль в развитии осложнений беременности и в их профилактике у женщин с гипертонической болезнью и хроническим гломерулонефритом. Терапевтический архив 1997; 69(6):17–21 [Zozulya OV, Rogov VA, Pyatakova NV, Tareeva IE. Oksid azota: rol' v razvitii oslozhnenij beremennosti i v ih profilaktike u zhenshchin s gipertonicheskoj bolezn'yu i hronicheskim glomerulonefritom. Terapevticheskij arhiv 1997;69(6):17–21]
40. Sugimoto H, Hamanog Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. Journal of Biological Chemistry 2003;278(15):12605–12608. doi.org/10.1074/jbc.C300012200
41. Henao DE, Mathieson PW, Saleem MA et al. A novel renal perspective of preeclamsia: a look from the podocyte. Nephrol Dial Transplant 2007;22(5): 1477 .doi:10.1093/ndt/gf1804
42. Garovic V, Wagner S, Petrovic L et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007;22: 1136–1143. doi.org/10.1093/ndt/gfl711
43. Garovic VD, Wagner SJ, Turner ST. Urinary podocyte excretion as a marker for preeclampsia. Am J Obst Gynecol 2007; 196: 320–327. dx.doi.org/10.1016/j.ajog.2007.02.007
44. Aita K, Etoh M, Hamada H et al. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Practice 2009; 112: 65–70. doi: 10.1159/000213083
45. Craici I M, Steven J. Wagner, Kent R. Bailey at all. Podocyturia Predates Proteinuria and Clinical Features of Preeclampsia. Hypertension 2013;61:6 1289–1296. doi.org/10.1161/HYPERTENSIONAHA.113.01115
46. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974. doi.org/10.1136/bmj.39335.385301.BE
47. Rodie V, Freeman DJ, Sattar N et al. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy. Atherosclerosis 2004; 175(2): 189–202. doi.org/10.1016/j.atherosclerosis.2004.01.038
48. Vikse В, Lorentz M. Irgens et al. Preeclampsia and the Risk of End-Stage Renal Diseasе. Engl J Med 2008; 359: 800–809. doi.org/10.1056/NEJMoa0706790
49. Munkhaugen J, Vikse BE. New aspects of pre-eclamsia: lessons for the nephrologist. Nephrol Dial Transplant 2009; 3 pages.doi:10.1093/ndt/gfp341
50. Bar J, Kaplan B, Wittenberg C et al. Microalbuminuria after pregnancy complicated by preeclampsia. Nephrol Dial Transplant 1999; 14: 1129–1132. doi.org/10.1093/ndt/14.5.1129
51. Nisell H, Lintu H, Lunell NO et al. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol 1995;102: 876–881. doi.org/10.1111/j.1471-0528.1995.tb10874.x
52. Abbate M, Zoja C, Rumuzzi G. How does proteinuria cause progressive renal damage? J Am Sos Nephrol 2006; 17: 2974–2984. doi.org/10.1681/ASN.2006040377
53. Murakami S, Saitih M, Kubo T et al. Renal desease in woman with severe preeclampsia or gestational proteinuria. Obstet Gynaecol 2000; 96: 945–949. doi.org/10.1016/S00297844(00)01055-3
54. Reiter L, Brown MA, Whitworth JA. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am J Kidney Dis 1994; 24: 883–887. doi.org/10.1016/ S0272-6386(12)81055-9
55. Ihle BU, Long P, Oats J. Early onset preeclampsia: Recognition of underlying renal disease. Br Med J (Clin Res Ed)1987; 294:79. DOI: 10.1016/0020-7292(87)90109-3
56. Poon LCY, Kametas NA, Maiz N et al. First – trimestre prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812–818. doi: 10.1161/HYPERTENSIONAHA.108.127977
Для цитирования:
Меркушева Л.И., Козловская Н.Л. ПОРАЖЕНИЕ ПОЧЕК ПРИ ПРЕЭКЛАМПСИИ: ВЗГЛЯД НЕФРОЛОГА (ОБЗОР ЛИТЕРАТУРЫ). Нефрология. 2018;22(2):30-38. https://doi.org/10.24884/1561-6274-2018-22-2-30-38
For citation:
Merkusheva L.I., Kozlovskaya N.L. RENAL INJURY IN PREECLAMPSIA: THE VIEW OF NEPHROLOGIST (LITERATURE REVIEW). Nephrology (Saint-Petersburg). 2018;22(2):30-38. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-2-30-38
Просмотров: 7
Послать статью по эл. почте 